Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8 and CDK19 inhibitor (IC50s: 0.61 nM and 4.28 nM). STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,730 | 5日内发货 | ||
5 mg | ¥ 2,690 | 5日内发货 | ||
25 mg | ¥ 9,390 | 6-8周 | ||
50 mg | ¥ 12,200 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,830 | 5日内发货 |
AS2863619 free base 的其他形式现货产品:
产品描述 | AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8 and CDK19 inhibitor (IC50s: 0.61 nM and 4.28 nM). STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene. |
靶点活性 | CDK19:4.28 nM, CDK8:0.61 nM, STAT5:, GSK-3α:76.67 nM, GSK-3β:63.06 nM |
体外活性 | AS2863619 (1 μM; 22 hours; mouse CD4+ T cells) treatment suppresses serine phosphorylation of the PSP motif of STAT5b to ~40% while enhancing tyrosine phosphorylation in the C-terminal domain to ~160% of control-treated samples. |
体内活性 | AS2863619 (30 mg/kg; p.o.; daily; for 2 weeks; mice) treatment after sensitization with DNFB dampens the degree of the secondary response, with milder infiltration of inflammatory cells into the skin and decreases ratios of IFN-γ+ cells in a skin contact hypersensitivity model, when compared with vehicle-treated control mice. Treg depletion before the elicitation of the secondary response abolishes AS2863619-induced suppression. KLRG1+ Foxp3+ T cells are specifically increased in DNFB sensitized AS2863619-treated mice. |
分子量 | 332.32 |
分子式 | C16H12N8O |
CAS No. | 2241300-50-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (752.29 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.0091 mL | 15.0457 mL | 30.0915 mL | 75.2287 mL |
5 mM | 0.6018 mL | 3.0091 mL | 6.0183 mL | 15.0457 mL | |
10 mM | 0.3009 mL | 1.5046 mL | 3.0091 mL | 7.5229 mL | |
20 mM | 0.1505 mL | 0.7523 mL | 1.5046 mL | 3.7614 mL | |
50 mM | 0.0602 mL | 0.3009 mL | 0.6018 mL | 1.5046 mL | |
100 mM | 0.0301 mL | 0.1505 mL | 0.3009 mL | 0.7523 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AS2863619 free base 2241300-50-3 Cell Cycle/Checkpoint CDK AS-2863619 AS-2863619 free base AS 2863619 AS2863619 Inhibitor inhibitor inhibit